US ▾
AYTU
Earnings call · Jun 2026 (Q4 FY26)

AYTU BIOPHARMA Q4 FY26 earnings call AYTU

Sep 22, 2026 Source

Executive summary

Aytu BioPharma Q4 FY26 — EXXUA Momentum and Return to Positive Adjusted EBITDA

Aytu BioPharma concluded fiscal 2026 with an encouraging fourth quarter, marked by strong momentum in its EXXUA launch and a return to positive adjusted EBITDA. The company is employing a methodical, data-driven approach to commercial investment, focusing on sales force productivity and cash preservation. The legacy ADHD business continues to provide a durable source of cash flow, supporting the strategic build-out of EXXUA.

Highlights

5

  • EXXUA net revenue grew to $3.9 million in Q4 FY26, up from $2.4 million in Q3 FY26.

  • Aytu returned to positive adjusted EBITDA of $0.5 million in Q4 FY26, compared to a negative $2.8 million in Q3 FY26.

  • EXXUA sales specialist productivity more than doubled, from ~18 prescriptions per rep per month in March to ~43 in July.

  • The ADHD portfolio performed better than anticipated, generating $10.4 million in net revenue in Q4 FY26, up from $9.1 million in Q3 FY26.

  • EXXUA gross-to-nets are significantly higher than initial expectations, with prior authorization approval rates around 70%.

Concerns

2

  • ADHD portfolio net revenue of $10.4 million in Q4 FY26 was down from $13.1 million in the prior year period.

  • Sales force adjustments temporarily reduced EXXUA coverage, with headcount dropping from 43 reps in March to 32 in July, before recovering to 42.

Guidance & targets

CategoryTargetConfidence
Operating expenses (GAAP)
$49 million to $54 million
high materiality
High
Cash-based operating expenses
$45 million to $49 million
high materiality
High
Sales and marketing investment
up to $6 million increase
medium materiality
High
Consolidated gross margin
approach 66% to 67%
medium materiality
Medium
Adjusted EBITDA
positive
high materiality
Medium
Cash flow
improve
high materiality
Medium

Segment performance

SegmentRevenueYoYQoQMargin
EXXUA
EXXUA showed strong sequential revenue and prescription growth in its first full quarter of launch, with continued momentum into Q1 FY27. The company is focused on building prescriber base and expanding commercial activity.
Net revenue (Q3 FY26): $2.4MNet revenue (FY26): $6.6MTotal prescriptions (Q4 FY26): 3,323Total prescriptions (Q3 FY26): 1,398Monthly prescriptions (April): 973Monthly prescriptions (May): 1,089Monthly prescriptions (June): 1,261Monthly prescriptions (July): 1,377Monthly prescriptions (August): 1,408Units shipped (Q4 FY26): 4,599
$3.9M—62.5%—
ADHD Portfolio
The ADHD portfolio performed better than anticipated in Q4 FY26, with sequential revenue improvement driven by better gross-to-net realization. It remains an important source of cash flow with limited promotional spending.
Net revenue (Q3 FY26): $9.1MNet revenue (prior year Q4): $13.1MAdzenys/AG prescription retention: ~80%
$10.4M-20.6%14.3%—
Pediatric Portfolio
The pediatric portfolio, consisting of mature products, showed strong sequential revenue growth in Q4 FY26 and continues to be a useful and durable contributor to the legacy business and financial foundation for EXXUA.
Net revenue (Q3 FY26): $0.9MNet revenue (prior year Q4): $2.0M
$1.8M-10.0%100.0%—

Risks & headwinds

Variability in quarterly results Quarterly

Not quantified

Mitigation:Management will continue to invest and manage the business through normal seasonal patterns.

ADHD business seasonality H1 FY27

Softer in first half of fiscal year

Mitigation:Anticipated and factored into financial outlook, with expected reversal in the second half.

PDUFA fees H1 FY27

Annual fees

Mitigation:Expected to impact cash flow in the first half of the fiscal year.

What to watch in Q1 FY27

EXXUA sales force headcount and productivity

Next quarter
Current 42 representatives; ~43 prescriptions/rep/month (July)
Target Increased headcount (closer to 45+); continued improvement in prescriptions/rep

Why it matters

Sales force expansion and productivity are key drivers for EXXUA's growth and profitability, especially as new reps ramp up.

Since that low, we brought the sales force back to approximately 42 representatives, and we continue to fill open positions. We're also adjusting territory coverage based on what we're learning, adding resources where the opportunity to support them and combining sales specialist coverage where that makes better economic sense.

Q&A highlights

Can you elaborate on the factors contributing to the more favorable-than-expected GTN discount for EXXUA?

The favorable GTN is primarily due to higher-than-anticipated approval rates across commercial payers, which are holding consistently month-to-month. Approval rates for the titration pack are also materially higher than modeled. The growing percentage of government business (Medicaid/Medicare), which typically has better GTNs, is also a factor, with some analog products reaching 35-40% government business. This is occurring without any commercial contracts or supplemental rebates.

“In short, it's just a higher-than-anticipated approval rate, really across commercial payers. That's a simple answer. We're seeing it consistent. We're seeing it hang on really month-to-month.”

asked by Thomas Flaten · answered by Joshua Disbrow

2 min read 5 chapters

Detailed narrative

EXXUA Launch Strategy and Performance

Aytu is executing a methodical, productivity-focused launch for EXXUA, aiming for strong return on commercial investment and cash preservation. EXXUA generated $3.9 million in net revenue in Q4 FY26, up from $2.4 million in Q3 FY26, with total prescriptions reaching 3,323 in Q4, compared to 1,398 in Q3. Monthly prescriptions continued to grow into Q1 FY27, reaching 1,408 in August. The company has completed its first full quarter of launch, focusing on building physician awareness and expanding the prescription base.

Sales Force Optimization and Productivity

The EXXUA sales force underwent intentional adjustments to demand high performance, leading to a temporary reduction from 43 representatives in March to a low of 32 in July, before recovering to approximately 42. This optimization significantly improved productivity, with prescriptions per sales rep per month increasing from ~18 in March to ~43 in July. The top 10 active sales specialists are averaging almost 15 prescriptions per week, and 24 territories (60% of the sales force) are driving 70% of EXXUA prescriptions, indicating broad adoption potential.

ADHD Portfolio Durability

The ADHD portfolio demonstrated better-than-anticipated performance in Q4 FY26, with net revenue of $10.4 million, up from $9.1 million in Q3 FY26. The Adzenys brand and authorized generic continue to retain approximately 80% of prescriptions in the market. The Cotempla authorized generic is gaining prescriptions, and Teva has not yet launched its generic version, presenting potential upside. This portfolio remains a crucial source of profit and cash to support EXXUA investments, despite limited promotional spending.

Gross-to-Net and Payer Dynamics

EXXUA is experiencing significantly more favorable gross-to-nets than initially expected, driven by higher-than-anticipated approval rates across commercial payers. Prior authorization approval rates are approximately 70%, which is materially higher than most categories. The company is not proactively pursuing commercial contracts or supplemental Medicaid/Medicare rebates, as current approval rates are strong, and payer contracts do not directly drive demand. The RxConnect program continues to be an important part of patient access, ensuring patients pay no more than $50 on commercial claims.

Financial Discipline and Cash Management

Aytu returned to positive adjusted EBITDA of $0.5 million in Q4 FY26 and maintained relatively stable cash and cash equivalents at $26.3 million. The company generated $3.3 million of cash from operating activities in FY26, an improvement of $5.2 million YoY, primarily due to improved receivable collections and inventory turnover. Significant balance sheet deleveraging occurred, with the revolving credit facility balance repaid subsequent to year-end and term debt reduced to approximately $11 million.

AI-generated summary of the company's earnings call. Not investment advice.